Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder
May 26, 2022 09:30 ET
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end VANCOUVER, May 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF,FSE: CWY0) (“Clearmind” or the...
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24, 2022 08:30 ET
|
Clearmind Medicine Inc.
Pre-clinical trial based on the proprietary combination demonstrates high safety profile in addition to a significant suppressive effect on alcohol consumption Vancouver, May 24, 2022 ...
Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
May 19, 2022 08:15 ET
|
Clearmind Medicine Inc.
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Announces Pre-IND Meeting Date with FDA
May 13, 2022 09:30 ET
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end Vancouver, May 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or...
Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors
May 10, 2022 08:30 ET
|
Clearmind Medicine Inc.
Pre-clinical trials based on proprietary combination demonstrate significant suppressive effect on alcohol consumption TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals
May 09, 2022 09:30 ET
|
Clearmind Medicine Inc.
Prof. Schütz’ main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses; Prof. Weiser specializes in psychiatric disorders such...
Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th
March 24, 2022 15:00 ET
|
Clearmind Medicine Inc.
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the...
Clearmind Medicine Announces Positive Results on CMND-100 trials
March 17, 2022 08:00 ET
|
Clearmind Medicine Inc.
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration
March 08, 2022 08:30 ET
|
Clearmind Medicine Inc.
The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. TORONTO, March 08, 2022 (GLOBE...
Clearmind Medicine to Host a "Psychedelics for Alcoholism" Event for Investors on February 23
February 17, 2022 09:00 ET
|
Clearmind Medicine Inc.
Market analyst Marissa Wright discusses the psychedelics market with a focus on psychedelic treatments for alcohol use disorder TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...